Education
About Us
Working with TipRanks
Follow Us
Daito Pharmaceutical Co., Ltd. (JP:4577)
:4577
4577 Stock Chart & Stats
¥1356.00
-¥13.00(-0.64%)
At close: 4:00 PM EST
¥1356.00
-¥13.00(-0.64%)
Day’s Range― - ―
52-Week Range¥970.00 - ¥1,395.00
Previous CloseN/A
Volume21.10K
Average Volume (3M)63.87K
Market Cap
¥41.10B
Enterprise Value¥49.17B
Total Cash (Recent Filing)¥2.15B
Total Debt (Recent Filing)¥11.94B
Price to Earnings (P/E)18.4
Beta0.28
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.75%
Share Statistics
EPS (TTM)N/A
Shares Outstanding30,096,880
10 Day Avg. Volume54,390
30 Day Avg. Volume63,866
Financial Highlights & Ratios
PEG Ratio-0.39
Price to Book (P/B)0.58
Price to Sales (P/S)0.59
P/FCF Ratio-31.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained top-line growth near 7% indicates durable demand for the company’s products and expanding market reach. Over a 2–6 month horizon this supports stable sales momentum, helps absorb fixed costs, and provides a base for funding R&D or incremental marketing to further entrench market share.
Stable Capital StructureA stable equity ratio signals a resilient capital base that cushions operational shocks and preserves borrowing capacity. This durability supports investment in pipelines or manufacturing, reduces insolvency risk, and gives management optionality to finance growth without immediate dilutive equity moves.
Diversified Revenue StreamsRevenue from both prescription and OTC products, plus partnership/licensing channels, creates multiple cash sources and lowers single-product concentration risk. Structurally this diversification stabilizes cash inflows and makes near-term revenue less vulnerable to individual regulatory or competitive setbacks.
Bears Say
Declining MarginsMaterial margin compression reduces internal funding for R&D, marketing, and capital needs and signals pricing pressure or rising input costs. Persistently lower gross and net margins weaken return on invested capital and increase dependence on volume gains or cost restructuring to restore sustainable profitability.
Rising LeverageA rising debt burden raises interest and refinancing risk and curtails financial flexibility. Even if still moderate, the trend reduces capacity to fund opportunistic investments or weather shocks, and makes the company more sensitive to higher rates or cash-flow shortfalls over the medium term.
Negative Free Cash FlowPersistent negative free cash flow forces reliance on external financing or asset sales to fund operations and service debt. This constrains strategic options, increases execution risk for new product launches, and can pressure dividends or capital allocation priorities over a 2–6 month horizon.
Daito Pharmaceutical Co., Ltd. News
4577 FAQ
What was Daito Pharmaceutical Co., Ltd.’s price range in the past 12 months?
Daito Pharmaceutical Co., Ltd. lowest stock price was ¥970.00 and its highest was ¥1395.00 in the past 12 months.
What is Daito Pharmaceutical Co., Ltd.’s market cap?
Daito Pharmaceutical Co., Ltd.’s market cap is ¥41.10B.
When is Daito Pharmaceutical Co., Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Daito Pharmaceutical Co., Ltd.’s earnings last quarter?
Currently, no data Available
Is Daito Pharmaceutical Co., Ltd. overvalued?
According to Wall Street analysts Daito Pharmaceutical Co., Ltd.’s price is currently Overvalued.
Does Daito Pharmaceutical Co., Ltd. pay dividends?
Daito Pharmaceutical Co., Ltd. pays a Semiannually dividend of ¥20 which represents an annual dividend yield of 2.75%. See more information on Daito Pharmaceutical Co., Ltd. dividends here
What is Daito Pharmaceutical Co., Ltd.’s EPS estimate?
Daito Pharmaceutical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Daito Pharmaceutical Co., Ltd. have?
Daito Pharmaceutical Co., Ltd. has 30,096,880 shares outstanding.
What happened to Daito Pharmaceutical Co., Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Daito Pharmaceutical Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4577
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Daito Pharmaceutical Co., Ltd.
Daito Pharmaceutical Co.,Ltd. manufactures and sells pharmaceutical products worldwide. The company offers various active pharmaceutical ingredients and intermediates, prescription drugs, OTC drugs, and home-delivery medicines; formulations in various forms, such as tablets, capsules, troches, granules, and powders; and contract manufacturing services for formulations of medicinal products to pharmaceutical companies. It also sells health food products. The company was formerly known as Daito Corporation and changed its name to Daito Pharmaceutical Co.,Ltd. in 1992. Daito Pharmaceutical Co.,Ltd. was incorporated in 1942 and is headquartered in Toyama, Japan.
Technical Analysis
Fuji Pharma Co., Ltd.
―
Pharma Foods International Co., Ltd.
―
Fuso Pharmaceutical Industries,Ltd.
―
Taiko Pharmaceutical Co., Ltd.
―
Mizuho Medy Co., Ltd.
―
Options Prices
Currently, No data available
---